CURRENT
ISSUE
1572
May 20, 2019
The FDA has approved Inbrija (Acorda), an orally
inhaled dry-powder formulation of levodopa, for
intermittent treatment of "off" episodes in patients
with Parkinson's disease (PD) being treated with
carbidopa/levodopa (Sinemet, and others).... Continue reading
More from Issue 1572
Previous Issue: 1571 May 6, 2019
- Insulins for Type 2 Diabetes
- Brexanolone (Zulresso) for Postpartum Depression
- Siponimod (Mayzent) - A New Drug for Multiple Sclerosis
- In Brief: Tegaserod (Zelnorm) Returns
- Expanded Table: Some Available Insulins for Type 2 Diabetes (online only)
Coming Soon
Drugs for Psoriasis
Romosozumab (Evenity) for Postmenopausal Osteoporosis
Prucalopride (Motegrity) for Chronic Idiopathic Constipation
Risankizumab (Skyrizi) for Psoriasis
Tafenoquine (Arakoda and Krintafel) for Malaria
Subscribe
Tweets
FROM
ISSUE
1572
The FDA has approved omadacycline (Nuzyra – Paratek),
a semisynthetic tetracycline derivative, for once-daily
IV and oral treatment of community-acquired bacterial
pneumonia (CAP) and acute bacterial skin and skin
structure infections (ABSSSIs) in adults. ... Continue reading
